CA2650616A1 - Hepatitis c virus infection biomarkers - Google Patents

Hepatitis c virus infection biomarkers Download PDF

Info

Publication number
CA2650616A1
CA2650616A1 CA002650616A CA2650616A CA2650616A1 CA 2650616 A1 CA2650616 A1 CA 2650616A1 CA 002650616 A CA002650616 A CA 002650616A CA 2650616 A CA2650616 A CA 2650616A CA 2650616 A1 CA2650616 A1 CA 2650616A1
Authority
CA
Canada
Prior art keywords
activity
binding
subject
protein
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002650616A
Other languages
English (en)
French (fr)
Inventor
Ravi K. Ramachandran
Matthew W. Harding
Paul R. Caron
Martyn C. Botfield
Brian J Hare
Raj Bandaru
Kevin M Kelliher
Catharine N. Cornell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2650616A1 publication Critical patent/CA2650616A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/706Specific hybridization probes for hepatitis
    • C12Q1/707Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00Reactions characterised by their quantitative nature
    • C12Q2545/10Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002650616A 2006-04-26 2007-04-25 Hepatitis c virus infection biomarkers Abandoned CA2650616A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79552006P 2006-04-26 2006-04-26
US60/795,520 2006-04-26
PCT/US2007/067421 WO2007127801A2 (en) 2006-04-26 2007-04-25 Hepatitis c virus infection biomarkers

Publications (1)

Publication Number Publication Date
CA2650616A1 true CA2650616A1 (en) 2007-11-08

Family

ID=38656353

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002650616A Abandoned CA2650616A1 (en) 2006-04-26 2007-04-25 Hepatitis c virus infection biomarkers

Country Status (13)

Country Link
US (1) US20100028874A1 (https=)
EP (1) EP2016195A4 (https=)
JP (1) JP2009535036A (https=)
KR (1) KR20090023360A (https=)
CN (1) CN101479389A (https=)
AU (1) AU2007244824A1 (https=)
CA (1) CA2650616A1 (https=)
IL (1) IL194920A0 (https=)
MX (1) MX2008013796A (https=)
NO (1) NO20084954L (https=)
NZ (1) NZ573052A (https=)
RU (1) RU2008146518A (https=)
WO (1) WO2007127801A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
JP2009178057A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット
EA201170484A1 (ru) * 2008-09-24 2012-03-30 Вертекс Фармасьютикалз Инкорпорейтед Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
US9709565B2 (en) 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
CN102323426A (zh) * 2011-08-08 2012-01-18 中国人民解放军军事医学科学院放射与辐射医学研究所 用于诊断或筛查丙型肝炎病毒感染的试剂
EP3367099B1 (en) 2012-02-09 2021-05-26 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US10799567B2 (en) 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
WO2016026258A1 (en) * 2014-08-22 2016-02-25 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS
IL287757B (en) 2016-03-03 2022-07-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
AU2017278254A1 (en) * 2016-06-07 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of bacterial and viral infections
EP3482200B1 (en) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
EP3482201B1 (en) 2016-07-10 2022-12-14 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
CN110448548B (zh) * 2018-05-08 2023-05-05 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램
CN111333710B (zh) * 2020-03-04 2021-12-03 暨南大学 C20orf24蛋白缺失突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407587A (pt) * 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
US20050282179A1 (en) * 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients
WO2006072075A2 (en) * 2004-12-30 2006-07-06 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia

Also Published As

Publication number Publication date
KR20090023360A (ko) 2009-03-04
WO2007127801A3 (en) 2008-09-12
IL194920A0 (en) 2009-08-03
EP2016195A4 (en) 2010-03-10
CN101479389A (zh) 2009-07-08
JP2009535036A (ja) 2009-10-01
AU2007244824A1 (en) 2007-11-08
NO20084954L (no) 2009-01-22
EP2016195A2 (en) 2009-01-21
WO2007127801A2 (en) 2007-11-08
US20100028874A1 (en) 2010-02-04
NZ573052A (en) 2012-03-30
MX2008013796A (es) 2009-03-31
RU2008146518A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
US20100028874A1 (en) Hepatitis c virus infection biomarkers
Meissner et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
Abe et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy
EP2115169B1 (en) Methods for determining drug sensitivity in patients infected with hcv
EP3822367A1 (en) Detection processes using sites of chromosome interaction
Welzel et al. Variants in interferon‐alpha pathway genes and response to pegylated interferon‐Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long‐term treatment against cirrhosis trial
JP2007529714A (ja) 遺伝子分析のための方法
AU2009240021A1 (en) Antiviral therapy
US10072296B2 (en) Compositions and methods for sjögren's syndrome
EP2191274A1 (en) Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
US20230332230A1 (en) Biomarkers and uses thereof in the treatment of chronic hepatitis b infection
JP2023055222A (ja) クロストリジウム・ディフィシレ毒素bを標的化する治療に対する応答に関連したヒト遺伝的マーカー
Macartney et al. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure
KR102101807B1 (ko) 인슐린 저항성 진단용 조성물 및 이의 용도
Ren et al. Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection
Jain Personalized therapy of infectious diseases
Wu et al. A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-α treatment in chronic hepatitis B patients
WO2018107388A1 (en) Human genetic markers associated with response to treatments that target clostridium difficile toxin b
HK1130843A (en) Hepatitis c virus infection biomarkers
Benish et al. Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations
ARDYANTO et al. Vitamin K Epoxide Reductase Complex, Subunit 1 Gene-1639 Polymorphism in Surakarta, Indonesia and South East Asia.
EP4058595A1 (en) Methods for using low-dose colchicine after myocardial infarction
HK40079722A (en) Biomarkers and uses thereof in the treatment of chronic hepatitis b infection
Ansari et al. Interferon lambda 4 impacts broadly on hepatitis C virus diversity
Omri Characterization of human septic sera induced gene expression modulation in human myocytes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140425